Viking Therapeutics
VKTX
$25.17
-8.04%
Viking Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel, orally administered therapies for metabolic and endocrine disorders, with a pipeline led by VK2735 (a dual GLP-1/GIP receptor agonist for obesity and metabolic disease), VK2809 (a thyroid hormone receptor beta agonist for NASH/MASH), and earlier-stage assets including VK5211 and VK0214. As a small-cap, pre-revenue biotech with roughly 65 employees and a market capitalization near $4.0 billion, Viking is best characterized as a high-conviction, catalyst-driven pipeline story rather than a commercial operator, deriving essentially all of its equity value from the probability-weighted success of its clinical programs. The current investor narrative is dominated by VK2735's advancement into Phase 3 testing for obesity, where impressive weight-loss and maintenance data have positioned the company as a potential challenger to Eli Lilly and Novo Nordisk in the GLP-1 market, while debate centers on high discontinuation rates, competitive intensity, and the dilutive capital raises required to fund late-stage development. Recent headlines capture this tension: shares spiked on strong VK2735 maintenance data in late September, then slumped on a subsequent capital raise, with sell-side bulls (e.g., Oppenheimer's $120 target) framing the pullback as an entry point while skeptics emphasize binary clinical and financing risk.…
VKTX
Viking Therapeutics
$25.17
Related headlines
VKTX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viking Therapeutics's 12-month outlook, with a consensus price target around $94.50 and implied upside of +275.4% versus the current price.
Average Target
$94.50
0 analysts
Implied Upside
+275.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$38 - $125
Analyst target range
Coverage is robust for a mid-cap biotech, with 20 analysts and a consensus recommendation of 'strong_buy' (mean rating of 1.43 on a 1-to-5 scale where 1 is Strong Buy). The average target price of $94.50 implies roughly +275% upside from the current $25.17, an extraordinarily wide gap that reflects the binary, catalyst-driven nature of the name rather than near-term earnings support. The consensus is unambiguously bullish, and the institutional ratings history shows a wall of reiterations — Truist (Buy, Sept 23, 2026), JP Morgan (Overweight, Aug 11, 2026), Canaccord (Buy, July 30, 2026), BTIG (Buy, May 1, 2026), Cantor Fitzgerald (Overweight, April 30, 2026), and HC Wainwright (Buy, March 23, 2026) — with no downgrades in the visible record, indicating analysts are holding conviction through the drawdown.
The target range spans $38.00 to $125.00, a spread of more than 3x, which signals very high uncertainty and divergent assumptions about VK2735's commercial trajectory. The high end (Oppenheimer's $120, per recent coverage) assumes successful Phase 3 execution, differentiated oral dosing, and meaningful share capture in the obesity market — essentially a full pipeline-success scenario. The low end of $38.00 still implies about +51% upside and likely prices in clinical delays, competitive pressure from Eli Lilly, or dilution, but not outright failure. The consensus estimated EPS of $2.57 and estimated revenue of $1.23 billion (both single-point estimates in the data) imply analysts expect a dramatic inflection to profitability and commercialization, which is the crux of the bull case; investors should treat the average target as a probability-weighted option value rather than a near-term price objective, and note that the tight clustering of reiterated Buy/Overweight ratings alongside a 3x target spread is characteristic of high-conviction but high-variance clinical-stage coverage.
Bulls vs Bears: VKTX Investment Factors
The bear case currently has stronger evidence: the stock is pinned at its 52-week low, momentum is deteriorating across every horizon (relative strength -43.06% over one year), and the financing model guarantees recurring dilution. The bull case rests almost entirely on analyst conviction (20 strong_buy ratings, $94.50 average target) and the clinical promise of VK2735, which the market has so far refused to pay for. The single most important tension is whether VK2735's Phase 3 program can deliver clean, well-tolerated data that converts pipeline optionality into a credible commercial franchise — if it can, the 275% gap to consensus target closes rapidly; if tolerability or discontinuation rates disappoint, the equity has little fundamental floor. Until a higher low forms or a financing is completed on favorable terms, the risk/reward is asymmetric only for investors who can underwrite binary clinical outcomes.
Bullish
- Wall of analyst conviction at $94.50: All 20 covering analysts rate VKTX a consensus 'strong_buy' (mean 1.43), with an average target of $94.50 implying roughly +275% upside from $25.17. The visible ratings history shows only reiterations — Truist, JP Morgan, Canaccord, BTIG, Cantor and HC Wainwright — with no downgrades through a 27.5% one-year decline, suggesting the sell-side views the drawdown as sentiment-driven rather than fundamental.
- VK2735 maintenance data validated: The September 22-23, 2026 spike from $30.11 to $41.65 (+38% in two sessions) followed impressive VK2735 weight-loss and maintenance results, confirming the asset can move the equity violently on positive data. Oppenheimer's $120 target explicitly rests on this data plus oral dosing differentiation, framing VK2735 as a credible challenger to Lilly and Novo.
- Pristine balance sheet, no debt: Debt-to-equity is effectively zero at 0.0002 and the current ratio is 9.33, so there is no solvency risk in the near term. The company's problem is cash burn, not leverage — a distinction that matters because it means survival depends on access to equity markets, which remain open for obesity assets.
- De-rated to mid-range of own P/B band: Price-to-book has fallen from 11.07x in Q2 2026 to 6.20x today, versus a historical range of roughly 1.27x (Q1 2022) to 11.07x. The multiple is no longer at euphoric levels, meaning a Phase 3 success would re-rate the equity from a less extended starting point.
Bearish
- Falling knife at 52-week low: At $25.17 the stock sits just 0.9% above its 52-week low of $24.94 and 41.7% below its high of $43.15 — effectively at the bottom 1% of its range. It is down 14.74% in one month and 32.12% in three months, worse than the 27.53% one-year decline, meaning the selloff is accelerating, not stabilizing.
- Cash burn forces serial dilution: Free cash flow is -$418.44 million TTM with Q2 2026 operating cash flow of -$125.17 million, while cash fell to $125.75 million at June 30, 2026 from $165.81 million at year-end 2025. The September 2026 capital raise that triggered the slump is a template that will repeat until commercialization — each raise transfers value from existing holders.
- Losses widening, no revenue: Revenue is $0 every quarter; Q2 2026 net loss was -$128.02 million (EPS -$1.10) and operating expenses rose 78% year over year to $132.60 million from $74.57 million. The TTM loss of roughly $572 million against a $4.0 billion market cap shows the equity is a claim on future cash flows that do not yet exist.
- Clinical and competitive execution risk: Recent coverage flags high discontinuation rates for the oral obesity drug and strong competition from Eli Lilly, whose maintenance strategy and late-stage pipeline keep it the safer bet. A Phase 3 miss or a safety/tolerability problem would be binary and catastrophic for a stock with no revenue cushion.
VKTX Technical Analysis
VKTX is in a sustained, broad downtrend, with the stock down 27.53% over the trailing year and 28.94% year-to-date, a stark underperformance versus the S&P 500's +15.53% one-year and +11.93% YTD returns (relative strength of -43.06% and -40.87%, respectively). At the current price of $25.17, the stock sits just 0.9% above its 52-week low of $24.94 and 41.7% below its 52-week high of $43.15 — effectively trading at the very bottom of its 52-week range (roughly 1% of the range). This positioning signals persistent distribution and a lack of buyer conviction rather than a value cushion; a stock pinned near its lows after a year-long decline is a classic 'falling knife' profile until a higher low is established. The maximum drawdown of -40.26% over the period underscores the severity of the de-rating.
Short-term momentum is decisively negative and accelerating to the downside: the stock is down 14.74% over the past month and 32.12% over three months, both far worse than the one-year decline of 27.53%, indicating the selloff has intensified rather than stabilized. Relative strength is negative across every horizon (-15.96% vs. SPY over one month, -34.81% over three months, -35.97% over six months), confirming the weakness is idiosyncratic rather than market-driven. The most recent session saw an -8.04% single-day drop from $27.37 to $25.17 on elevated volume of roughly 7.57 million shares, a capitulation-style move that often accompanies news-driven selling (consistent with the September capital-raise reaction). Notably, the stock staged a violent spike from $30.11 on September 21 to $41.65 by September 23 on positive VK2735 data before fully retracing to current levels — evidence of extreme headline sensitivity and failed breakout dynamics.
Key technical levels are clearly defined: support rests at the 52-week low of $24.94, with the current price of $25.17 testing that floor; a decisive breakdown below $24.94 would signal a fresh leg lower and likely trigger momentum-driven selling. Resistance is anchored at the 52-week high of $43.15, with intermediate supply in the $36–$42 zone where the September spike failed. A breakout above resistance would require a fundamental catalyst (e.g., clean Phase 3 data or a partnership) rather than technical repair alone. The beta of 0.648 is deceptively low for a clinical-stage biotech — it reflects low correlation to the broad market rather than low absolute volatility, as evidenced by the 40%+ drawdown and double-digit single-day swings; position sizing should account for event risk, not just market beta.
Beta
0.65
0.65x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$25-$43
Price range past year
Annual Return
-27.5%
Cumulative gain past year
| Period | VKTX Return | S&P 500 |
|---|---|---|
| 1m | -14.7% | +0.2% |
| 3m | -32.1% | +2.9% |
| 6m | -28.5% | +8.4% |
| 1y | -27.5% | +14.9% |
| ytd | -28.9% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VKTX Fundamental Analysis
Viking is a pre-revenue company: reported revenue was $0 in Q2 2026, Q1 2026, and every quarter in the provided history, so traditional growth metrics do not apply. What is growing is the spending base — research and development expense rose from $41.39 million in Q1 2025 to $60.15 million in Q2 2025, $89.95 million in Q3 2025, $153.46 million in Q4 2025, $150.15 million in Q1 2026, and $115.75 million in Q2 2026, reflecting the ramp of late-stage VK2735 trials. Total operating expenses reached $132.60 million in Q2 2026 versus $74.57 million in the year-ago quarter, a 78% increase, which underscores that the investment case is entirely about future pipeline value rather than current financial performance.
The company is deeply unprofitable, with Q2 2026 net income of -$128.02 million (EPS of -$1.10) and EBITDA of -$127.87 million; gross margin is not meaningful (0%) given the absence of product revenue. The loss trajectory is widening, not narrowing: quarterly net losses progressed from -$24.94 million in Q3 2024 to -$45.63 million in Q1 2025, -$65.56 million in Q2 2025, -$90.79 million in Q3 2025, -$157.66 million in Q4 2025, -$158.33 million in Q1 2026, and -$128.02 million in Q2 2026. The sequential dip in Q2 2026 reflects timing of trial spend rather than a structural improvement, and the trailing twelve-month loss of roughly $572 million against a $4.0 billion market cap illustrates the scale of cash burn relative to equity value. Return on equity of -56.28% and return on assets of -51.86% confirm capital destruction during this investment phase.
Balance-sheet strength is the company's principal financial asset: debt-to-equity is effectively zero at 0.0002, and the current ratio of 9.33 (with a quick ratio of 4.72 as of Q2 2026) indicates ample near-term liquidity. However, free cash flow is deeply negative at -$418.44 million TTM, with quarterly operating cash flow of -$125.17 million in Q2 2026 and -$113.98 million in Q1 2026, and cash on hand fell to $125.75 million at June 30, 2026 from $165.81 million at year-end 2025 — a burn rate that necessitates repeated equity issuance (the September 2026 capital raise being the latest example). The FCF yield is negative and the price-to-free-cash-flow ratio of -14.22 is not economically meaningful; the key takeaway is that Viking depends entirely on external financing to fund development, making dilution risk a permanent feature of the investment case until commercialization or partnership revenue arrives.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-418441000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VKTX Overvalued?
Because Viking has negative net income (-$128.02 million in Q2 2026) and negative EBITDA (-$127.87 million), neither the trailing PE of -11.03 nor the forward PE of -5.78 nor the EV/EBITDA of -10.57 is economically meaningful; PS ratio is also unavailable (0) given zero revenue. The most informative metric is the price-to-book ratio of 6.20, which prices the equity at roughly 6.2x its accounting book value — a premium that reflects the market's capitalization of pipeline optionality (VK2735 Phase 3) rather than current assets. The gap between trailing PE (-11.03) and forward PE (-5.78) implies the market expects losses to narrow, but both remain negative, so the 'growth expectation' embedded is really a bet on eventual profitability from a commercial obesity franchise.
Peer comparison is constrained by the absence of a formal industry-average valuation dataset in the provided inputs, so a precise premium/discount spread cannot be quantified; however, contextually, large-cap obesity leaders such as Eli Lilly trade on positive earnings multiples in the tens, while pre-revenue GLP-1 challengers like Viking are valued on pipeline probability rather than earnings. Viking's 6.20x P/B versus its own historical range is instructive: the P/B has ranged from roughly 1.27x (Q1 2022) and 3.00x (Q3 2023) at the low end to 11.07x (Q2 2026) at the high end, with the current 6.20x sitting in the middle-to-upper portion of that band. The premium to book is therefore not extreme by the stock's own history but is elevated relative to the pre-2024 era, when the stock traded at 1–5x book before the obesity data re-rating.
Historically, Viking's valuation multiples have compressed as losses have widened: the trailing PE moved from -3.14x in Q2 2022 to -71.94x in Q3 2024 and back to -11.03x currently, a pattern driven by the denominator (losses) rather than a stable earnings base, so PE history offers limited signal. The more telling series is P/B, which peaked at 11.07x in Q2 2026 and has since drifted to 6.20x as the share price fell — meaning the market has de-rated the equity relative to its book value even as book value itself has been replenished by capital raises. This suggests the current valuation embeds meaningful but not euphoric optimism: it is neither at the historical top of its band nor at distressed levels, leaving the stock highly sensitive to Phase 3 data readouts rather than to multiple re-rating alone.
PE
-11.0x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by cash burn and dilution. Free cash flow is -$418.44 million TTM, Q2 2026 operating cash flow was -$125.17 million, and cash on hand fell to $125.75 million at June 30, 2026 from $165.81 million at year-end 2025 — a burn rate that cannot be funded internally. Research and development expense has ramped from $41.39 million in Q1 2025 to $115.75 million in Q2 2026, and total operating expenses rose 78% year over year to $132.60 million, so the funding requirement grows as Phase 3 scales. With zero revenue and a TTM net loss near $572 million, every quarter of delay or added trial site translates directly into more shares issued.
Market and competitive risks center on valuation compression and the GLP-1 arms race. The stock trades at 6.20x book — mid-to-upper in its historical 1.27x-11.07x band — which is a premium that assumes pipeline success rather than current assets, leaving room for further de-rating if sentiment sours. Beta of 0.648 understates true risk: the stock fell 40.26% at max drawdown and dropped 8.04% in a single session on 7.57 million shares, so volatility is idiosyncratic and event-driven. Competition from Eli Lilly and Novo Nordisk, plus reported high discontinuation rates for the oral formulation, threatens the commercial thesis before a single Phase 3 patient is enrolled.
The worst-case scenario is a Phase 3 safety or tolerability failure combined with a dilutive raise at distressed prices. In that chain, the stock breaks decisively below the $24.94 support, momentum selling accelerates, and the equity gravitates toward the analyst low target of $38.00 only in a benign miss — a true failure would push below the 52-week low toward book-value support implied by 6.20x P/B unwinding toward the 1-3x historical trough. From $25.17, a retest of the 52-week low is roughly -1%, but a full de-rating to the low end of the historical P/B band implies a loss of 50% or more; the realistic adverse case is a -35% to -50% drawdown to the $13-$16 range if financing occurs at trough prices.